Trial Profile
A multicenter, double-blind, parallel group, placebo controlled study of creatine in subjects with treated Parkinson's disease (PD) Long-term Study (LS-1)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Creatine monohydrate (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 05 Oct 2013 Planned end date changed from 1 May 2015 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 05 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Sep 2012 Planned end date changed from 1 Mar 2015 to 1 May 2015 as reported by ClinicalTrials.gov.